VASOACTIVE-INTESTINAL-PEPTIDE (VIP)(1) RECEPTOR - 3 NONADJACENT AMINO-ACIDS ARE RESPONSIBLE FOR SPECIES SELECTIVITY WITH RESPECT TO RECOGNITION OF PEPTIDE HISTIDINE ISOLEUCINEAMIDE
A. Couvineau et al., VASOACTIVE-INTESTINAL-PEPTIDE (VIP)(1) RECEPTOR - 3 NONADJACENT AMINO-ACIDS ARE RESPONSIBLE FOR SPECIES SELECTIVITY WITH RESPECT TO RECOGNITION OF PEPTIDE HISTIDINE ISOLEUCINEAMIDE, The Journal of biological chemistry, 271(22), 1996, pp. 12795-12800
Vasoactive intestinal peptide (VIP)(1) receptors in rats and humans re
cognize peptide histidine isoleucineamide (PHI) with high and low affi
nity, respectively. We took advantage of this phenotypic difference to
identify the domain responsible for the selective recognition of PHI
by rat and human receptors which display >80% sequence identity. After
transfection of human and rat receptors in COS cells, the ratio of IC
50 for PHI/IC50 for VIP (referred to as P/V) in inhibiting I-125-VIP b
inding was shown to be >1,000 and <40, respectively. Construction of e
ight rat/human receptor chimerae by overlap polymerase chain reaction
and determination of their P/V ratios demonstrated that the critical d
omain for PHI recognition is present within a sequence comprising part
of the first extracellular loop and third transmembrane domain. This
domain contains three different amino acids numbered according to huma
n and rat sequences, respectively, e.g. Gln(207) (human) versus His(20
8) (rat), Gly(211) versus Ala(212) and Met(219) versus Val(220). Site-
directed mutagenesis introducing individual, double, or triple mutatio
ns in a chimeric construct revealed that all three amino acids were in
volved in the recognition of PHI. Triple mutations were then introduce
d in the wild type receptors i.e. Q207H, G211A, M219V human VIP1 recep
tor and H208Q, A212G, V220M rat VIP1 receptor, resulting in a complete
change in their phenotype from human to rat and from rat to human, re
spectively. The results demonstrate that three nonadjacent amino acids
are responsible for the selective recognition of PHI by human and rat
VIP1 receptors.